Literature DB >> 10206496

Completion of tuberculosis therapy for patients reported in the United States in 1993.

A B Bloch1, G M Cauthen, P M Simone, G D Kelly, K G Dansbury, K G Castro.   

Abstract

SETTING: The highest priority for tuberculosis (TB) control is to ensure patients complete therapy. However, standardized, detailed evaluation of national performance on completion of therapy in the United States has been lacking. Since 1982, the Centers for Disease Control and Prevention (CDC) has had a program objective that at least 90% of TB cases complete therapy. Since 1986, the standard of practice for patients with drug-susceptible TB has been 6 months of therapy.
OBJECTIVE: To determine completion of therapy rates and duration of therapy for US TB patients reported in 1993.
DESIGN: Expanded TB surveillance data on all US TB patients reported to the CDC in 1993 with initial therapy of two or more drugs were analyzed with respect to completion and duration of therapy.
RESULTS: A disposition (reason therapy stopped) was obtained on 98.7% of 23 489 treated patients. Overall, 91.2% of evaluable patients completed therapy. The overall completion rate at 12 months of therapy was 66.8%, and 90% completion was reached at 23 months. For patients with initially drug-susceptible TB, completion was 7.1% at 6 months, 66.5% at 12 months, and reached 90% at 22 months.
CONCLUSION: While completion rates ultimately exceeded 90% nationwide, there was considerable delay in reaching this objective, especially in patients with drug-susceptible TB. It is critical that health departments and health care providers identify and remedy any deficiencies responsible for prolonged therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206496

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  The DOTs strategy. More than just watching patients take their tablets.

Authors:  A Fanning
Journal:  West J Med       Date:  1999-07

2.  Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992.

Authors:  J Peter Cegielski; Lenore Arab; Joan Cornoni-Huntley
Journal:  Am J Epidemiol       Date:  2012-07-11       Impact factor: 4.897

3.  Treatment duration for patients with drug-resistant tuberculosis, United States.

Authors:  Carla A Winston; Kiren Mitruka
Journal:  Emerg Infect Dis       Date:  2012-07       Impact factor: 6.883

4.  Generalizability in two clinical trials of Lyme disease.

Authors:  Daniel J Cameron
Journal:  Epidemiol Perspect Innov       Date:  2006-10-17

5.  Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia.

Authors:  Gebrehiwet Tesfahuneygn; Girmay Medhin; Mengistu Legesse
Journal:  BMC Res Notes       Date:  2015-09-29

6.  Tuberculosis treatment adherence and fatality in Spain.

Authors:  Joan A Caylà; Teresa Rodrigo; Juan Ruiz-Manzano; José A Caminero; Rafael Vidal; José M García; Rafael Blanquer; Martí Casals
Journal:  Respir Res       Date:  2009-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.